Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Business Insider

New Phase I Immunological Data Presented at SITC 2025 Support TG4050’s Potential Role in Preventing Cancer Relapse

New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC [*] patients Comprehensive immunogenicity data demonstrate TG4050’s ...
Seeking Alpha

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel ...
Reuters

Yifan Pharmaceutical Announces Successful Completion of Phase 1b Clinical Trial for Duanjin Jiedu Capsules

PRINCETON, NJ, September 26, 2025 (EZ Newswire) -- Opioid addiction, including dependence on substances such as fentanyl and heroin, is widely acknowledged as a global public health and social safety ...
Nasdaq

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for ...

SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., June 20, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of ...
Targeted Oncology

Teclistamab Improves PFS, OS in First Relapse of Multiple Myeloma

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...
USA Today

New Clinical Trial Aims to Prevent Relapse in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...
Nasdaq

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically ...
Yahoo Finance

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse

Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...
Mena FN

Transgene Publishes Phase I Data Supporting TG4050's Potential In Preventing Head And Neck Cancer Relapse

Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...